Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.83 |
| ▸ | NPC1 | O15118 | 4/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | HTT | P42858 | 3/20 | 0.83 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.83 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431864 | 0.91 | HTT (1.00) | RAB9ANPC1KMT2AHTTNCOA3 | |
| SCHEMBL19769183 | 0.74 | CHRM4 (1.00) | RAB9ANPC1KMT2AHTTNCOA3 | |
| SCHEMBL3172346 | 0.71 | HTT (0.55) | RAB9ANPC1KMT2AHTTNCOA3 | |
| SCHEMBL425233 | 0.69 | HTT (0.65) | RAB9ANPC1KMT2AHTTNCOA3 | |
| SCHEMBL12562466 | 0.68 | MAPT (0.84) | RAB9ANPC1KMT2AHTTALDH1A1 | |
| SCHEMBL14955057 | 0.68 | RAB9A (0.51) | RAB9ANPC1KMT2AHTTNCOA3 | |
| SCHEMBL14955139 | 0.66 | CHRM4 (0.68) | RAB9ANPC1KMT2AHTTNCOA3 | |
| SCHEMBL6217994 | 0.65 | MEN1 (0.53) | KMT2AHTTALDH1A1KDM4EMEN1 | |
| SCHEMBL9540888 | 0.64 | CHRM4 (0.69) | CHRM4ALDH1A1KDM4EMAPT | |
| SCHEMBL12562441 | 0.64 | MEN1 (0.74) | KMT2AHTTALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152301-A1 | Compounds that Inhibit HIV Particle Formation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152301-A1 | Compounds that Inhibit HIV Particle Formation | REV1, VPS51, FLOT1 | RAB9A 378/4885NPC1 68/4885KMT2A 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.